Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease

Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2021;18:56–66. https://doi.org/10.1038/s41575-020-00360-x.

Article  PubMed  Google Scholar 

Phelps NH, Singleton RK, Zhou B, Heap RA, Mishra A, Bennett JE et al. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. The Lancet 2024;403:1027–1050. https://doi.org/10.1016/S0140-6736(23)02750-2.

Article  Google Scholar 

Singh S, Dulai PS, Zarrinpar A, Ramamoorthy S, Sandborn WJ. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nature Reviews Gastroenterology and Hepatology 2017;14:110–121. https://doi.org/10.1038/nrgastro.2016.181.

Article  CAS  PubMed  Google Scholar 

Elangovan A, Shah R, Ali SMJ, Katz J, Cooper GS. High burden of obesity and low rates of weight loss pharmacotherapy in inflammatory bowel disease: 10-year trend. Crohn’s and Colitis 360 2023;5:1–8. https://doi.org/10.1093/crocol/otad007.

Article  Google Scholar 

Adolph TE, Meyer M, Schwärzler J, Mayr L, Grabherr F, Tilg H. The metabolic nature of inflammatory bowel diseases. Nature Reviews Gastroenterology and Hepatology 2022;19:753–767. https://doi.org/10.1038/s41575-022-00658-y.

Article  PubMed  Google Scholar 

Kim JH, Yoo JH, Oh CM. Obesity and novel management of inflammatory bowel disease. World Journal of Gastroenterology 2023;29:1779–1794. https://doi.org/10.3748/wjg.v29.i12.1779.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chan SSM, Luben R, Olsen A, Tjonneland A, Kaaks R, Teucher B et al. Body mass index and the risk for Crohn’s disease and ulcerative colitis: data from a European Prospective Cohort Study (The IBD in EPIC Study). The American Journal of Gastroenterology 2013;108:575–582. https://doi.org/10.1038/ajg.2012.453.

Article  PubMed  Google Scholar 

Bilski J, Mazur-Bialy A, Wojcik D, Surmiak M, Magierowski M, Sliwowski Z et al. Role of obesity, mesenteric adipose tissue, and adipokines in inflammatory bowel diseases. Biomolecules 2019;9:780. https://doi.org/10.3390/biom9120780.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nguyen NH, Ohno-Machado L, Sandborn WJ, Singh S. Obesity is independently associated with higher annual burden and costs of hospitalization in patients with inflammatory bowel diseases. Clinical Gastroenterology and Hepatology 2019;17:709-718.e7. https://doi.org/10.1016/j.cgh.2018.07.004.

Article  PubMed  Google Scholar 

Yin Y, Xie Y, Ge W, Li Y. Creeping fat formation and interaction with intestinal disease in Crohn’s disease. United European Gastroenterology Journal 2022;10:1077–1084. https://doi.org/10.1002/ueg2.12349.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khalili H, Ananthakrishnan AN, Konijeti GG, Higuchi LM, Fuchs CS, Richter JM et al. Measures of obesity and risk of Crohn’s disease and ulcerative colitis. Inflammatory Bowel Diseases 2015;21:361–368. https://doi.org/10.1097/MIB.0000000000000283.

Article  PubMed  Google Scholar 

Jensen CB., Ängquist LH., Mendall MA., Sørensen TIA., Baker JL., Jess T. Childhood body mass index and risk of inflammatory bowel disease in adulthood: a population-based cohort study. The American Journal of Gastroenterology 2018;113:694–701. https://doi.org/10.1038/s41395-018-0031-x.

Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. Journal of Biomedical Informatics 2009;42:377–381. https://doi.org/10.1016/j.jbi.2008.08.010.

Article  PubMed  Google Scholar 

Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L et al. The REDCap consortium: building an international community of software platform partners. Journal of Biomedical Informatics 2019;95:103208. https://doi.org/10.1016/j.jbi.2019.103208.

Article  PubMed  PubMed Central  Google Scholar 

Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine 2021;384:989–1002. https://doi.org/10.1056/nejmoa2032183.

Article  CAS  PubMed  Google Scholar 

Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine 2022;387:205–216. https://doi.org/10.1056/nejmoa2206038.

Article  CAS  PubMed  Google Scholar 

Desai A, Khataniar H, Hashash JG. Effectiveness and safety of semaglutide for weight loss in patients with inflammatory bowel disease and obesity. Inflammatory Bowel Diseases. 2024. https://doi.org/10.1093/ibd/izae090.

Article  PubMed  Google Scholar 

Villumsen M, Schelde AB, Jimenez-Solem E, Jess T, Allin KH. GLP-1 based therapies and disease course of inflammatory bowel disease. EClinicalMedicine 2021;37:100979. https://doi.org/10.1016/j.eclinm.2021.100979.

Article  PubMed  PubMed Central  Google Scholar 

Gao X, Hua X, Wang X, Xu W, Zhang Y, Shi C et al. Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Pharmacology 2022;13:1–14. https://doi.org/10.3389/fphar.2022.935823.

Article  CAS  Google Scholar 

Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kjær MS, Krarup N et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. The Lancet Gastroenterology and Hepatology 2023;8:511–522. https://doi.org/10.1016/S2468-1253(23)00068-7.

Article  CAS  PubMed  Google Scholar 

Siddiqui MS, Sterling RK, Luketic VA, Puri P, Stravitz RT, Bouneva I et al. Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology 2013;145:1271–1273. https://doi.org/10.1053/j.gastro.2013.08.036.

Article  CAS  PubMed  Google Scholar 

Calvarysky B, Dotan I, Shepshelovich D, Leader A, Cohen TD. Drug-drug interactions between glucagon-like peptide 1 receptor agonists and oral medications: a systematic review. Drug Safety 2024;47:439–451. https://doi.org/10.1007/s40264-023-01392-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Comments (0)

No login
gif